中国多发性骨髓瘤诊治指南(2024年修订)

Guidelines for the diagnosis and management of multiple myeloma in China(2024 revision)

多发性骨髓瘤(MM)是一种克隆浆细胞异常增殖的恶性疾病,在很多国家是血液系统第2位常见恶性肿瘤,多发于老年,目前仍无法治愈。随着新药不断问世及检测手段的提高,MM的诊断和治疗得以不断改进和完善。本次指南在诊断部分检查项目进行了更新;危险分层部分提出了超高危MM的定义;对于大于等于二线复发患者治疗增加了包含嵌合抗原受体T细胞疗法及双特异性抗体等方案的推荐;根据现有的最佳证据治疗建议以不同级别作为推荐。

Multiple myeloma (MM), an incurable clonal plasma cell dysplasia, is the second most common hematological malignancy in many countries, mainly developing in the elderly population. With the emergence of novel agents and laboratory methods, the diagnosis and treatment of MM have been significantly improved. In this version of the "Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)", several examination items have been updated in the diagnostic section;the definition of ultra high-risk MM has been proposed in the risk stratification section;for patients with equal or more than second-line relapse, chimeric antigen receptor T cell therapy and a bispecific T-cell engager have been added;and the treatment recommendations have been listed at different levels based on the best available evidence.